Safety and activity of the combination of ceritinib and dasatinib in osteosarcoma
Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF s...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 March 2020
|
| In: |
Cancers
Year: 2020, Jahrgang: 12, Heft: 4 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers12040793 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers12040793 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/12/4/793 
|
| Verfasserangaben: | Olaf Beck, Claudia Paret, Alexandra Russo, Jürgen Burhenne, Margaux Fresnais, Kevin Steimel, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Vewinger, Nadine Lehmann, Maximilian Sprang, Nora Backes, Lea Roth, Marie Astrid Neu, Arthur Wingerter, Nicole Henninger, Khalifa El Malki, Henrike Otto, Francesca Alt, Alexander Desuki, Thomas Kindler and Joerg Faber |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1725938014 | ||
| 003 | DE-627 | ||
| 005 | 20220818164225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200730s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers12040793 |2 doi | |
| 035 | |a (DE-627)1725938014 | ||
| 035 | |a (DE-599)KXP1725938014 | ||
| 035 | |a (OCoLC)1341348891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Beck, Olaf |d 1972- |e VerfasserIn |0 (DE-588)122360206 |0 (DE-627)705877558 |0 (DE-576)183037081 |4 aut | |
| 245 | 1 | 0 | |a Safety and activity of the combination of ceritinib and dasatinib in osteosarcoma |c Olaf Beck, Claudia Paret, Alexandra Russo, Jürgen Burhenne, Margaux Fresnais, Kevin Steimel, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Vewinger, Nadine Lehmann, Maximilian Sprang, Nora Backes, Lea Roth, Marie Astrid Neu, Arthur Wingerter, Nicole Henninger, Khalifa El Malki, Henrike Otto, Francesca Alt, Alexander Desuki, Thomas Kindler and Joerg Faber |
| 264 | 1 | |c 26 March 2020 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.07.2020 | ||
| 520 | |a Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF specific inhibitors and tested ceritinib as an off-target inhibitor, alone or in combination with dasatinib, on the proliferation of seven primary OS cells. Picropodophyllin, particularly in combination with dasatinib and the combination ceritinib/dasatinib were effective in abrogating the proliferation. The ceritinib/dasatinib combination was applied to the primary cells of a 16-year-old girl with a long history of lung metastases, and was more effective than cabozantinib and olaparib. Therefore, the combination was used to treat the patient. The treatment was well tolerated, with toxicity limited to skin rush and diarrhea. A histopathological evaluation of the tumor after three months of therapy indicated regions of high necrosis and extensive infiltration of macrophages. The extension of the necrosis was proportional to the concentration of dasatinib and ceritinib in the area, as analysed by an ultra performance liquid chromatography-tandem mass spectrometer (UPLC-MS/MS). After the cessation of the therapy, radiological analysis indicated a massive growth of the patient's liver metastases. In conclusion, these data indicate that the combination of ceritinib/dasatinib is safe and may be used to develop new therapy protocols. | ||
| 650 | 4 | |a ceritinib | |
| 650 | 4 | |a dasatinib | |
| 650 | 4 | |a osteosarcoma | |
| 700 | 1 | |a Burhenne, Jürgen |d 1963- |e VerfasserIn |0 (DE-588)1034228889 |0 (DE-627)745126987 |0 (DE-576)381858197 |4 aut | |
| 700 | 1 | |a Fresnais, Margaux |e VerfasserIn |0 (DE-588)1190043157 |0 (DE-627)1668720108 |4 aut | |
| 700 | 1 | |a Steimel, Kevin |e VerfasserIn |0 (DE-588)121484183X |0 (DE-627)1725939495 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 12(2020,4) Artikel-Nummer 793, 15 Seiten |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Safety and activity of the combination of ceritinib and dasatinib in osteosarcoma |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:4 |g extent:15 |a Safety and activity of the combination of ceritinib and dasatinib in osteosarcoma |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers12040793 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/12/4/793 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200730 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 121484183X |a Steimel, Kevin |m 121484183X:Steimel, Kevin |d 910000 |d 910100 |e 910000PS121484183X |e 910100PS121484183X |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 1190043157 |a Fresnais, Margaux |m 1190043157:Fresnais, Margaux |p 5 | ||
| 998 | |g 1034228889 |a Burhenne, Jürgen |m 1034228889:Burhenne, Jürgen |d 910000 |d 910100 |e 910000PB1034228889 |e 910100PB1034228889 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 999 | |a KXP-PPN1725938014 |e 3732859193 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"15 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2072-6694"],"eki":["614095670"],"zdb":["2527080-1"]},"origin":[{"publisherPlace":"Basel","dateIssuedKey":"2009","publisher":"MDPI","dateIssuedDisp":"2009-"}],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"part":{"year":"2020","issue":"4","volume":"12","text":"12(2020,4) Artikel-Nummer 793, 15 Seiten","extent":"15"},"pubHistory":["1.2009 -"],"language":["eng"],"recId":"614095670","disp":"Safety and activity of the combination of ceritinib and dasatinib in osteosarcomaCancers","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 27.05.2020"],"title":[{"title":"Cancers","title_sort":"Cancers"}]}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"26 March 2020"}],"id":{"doi":["10.3390/cancers12040793"],"eki":["1725938014"]},"name":{"displayForm":["Olaf Beck, Claudia Paret, Alexandra Russo, Jürgen Burhenne, Margaux Fresnais, Kevin Steimel, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Vewinger, Nadine Lehmann, Maximilian Sprang, Nora Backes, Lea Roth, Marie Astrid Neu, Arthur Wingerter, Nicole Henninger, Khalifa El Malki, Henrike Otto, Francesca Alt, Alexander Desuki, Thomas Kindler and Joerg Faber"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 30.07.2020"],"language":["eng"],"recId":"1725938014","title":[{"title":"Safety and activity of the combination of ceritinib and dasatinib in osteosarcoma","title_sort":"Safety and activity of the combination of ceritinib and dasatinib in osteosarcoma"}],"person":[{"family":"Beck","given":"Olaf","roleDisplay":"VerfasserIn","display":"Beck, Olaf","role":"aut"},{"given":"Jürgen","family":"Burhenne","role":"aut","display":"Burhenne, Jürgen","roleDisplay":"VerfasserIn"},{"given":"Margaux","family":"Fresnais","role":"aut","display":"Fresnais, Margaux","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Steimel, Kevin","given":"Kevin","family":"Steimel"}]} | ||
| SRT | |a BECKOLAFBUSAFETYANDA2620 | ||